Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Dyspnea in ILD
NCT04181359Phase 2Withdrawn
- Sponsor
- University of Alberta
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
01
Overview
Phase 2, randomised, double-blind trial in interstitial lung disease (ILD) comparing Nitric Oxide with Placebo (2 arms). Primary endpoint: Peak Oxygen Consumption (VO2peak). Planned start Sep 2024; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04181359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181359.